We would love to hear your thoughts about our site and services, please take our survey here.
Agree, good to see the end of JO. Did she add much value? She never had much skin in the game unlike JG and JM
Happy to see some new blood on the board but would have preferred a heavy hitter like Dr Wyllie or Dr Zhavoronkov both with solid industry experience, oh well
I doubt it is a simple pump and dump but rather accumulation by Haitong Securities during the past 3 weeks.
It is not uncommon for prof investors to sell a few shares during the accumulation phase in order to keep
the sp within a low trading band (fx. buy 40-50,000 then quickly dump 10,000..).
The share was sold down to a historical low of just 25c on very low volume so it should recover on low vol.
News on the NDA submission is not far away now and should get the sp moving.
I noticed an erratic 500k sell order @ 72c about 4-5 weeks ago, was that you Bignose, you are a HSBC trader right?
"7/6/23 0.59 hkd the low." Not correct, Ripley. I picked up another 50,000 shares @ 25c - now in safe hands.. lol
Interesting accumulation during the last few weeks by Haitong Securities
Futu Securities driving the rise today. These fellas are also the prime movers on the sustained New Ray Medic (6108) rally from 14c on April 6 to HK$2.51 today. Will 575 be the next 6108 runner?
Major rally in HK pharma stocks Bignose
Today Kaisa Health top the HK market - up 75%, # 2 is Uni Health with + 38%
New Ray Medic up +600% since last week on no news.. could this be the rally we all need to get back on track?
Indeed, time will tell. Maybe after all the BOD will manage to secure a superior US deal to the one Alquime noted in one of his 1,141 posts (exclusively on PLE): "Back in ancient times (2007), PLE concluded an exclusive US licence with Sciele on what might charitably be described as generous terms: no upfront (but $7m equity purchase, around 5.6% of the company); no development costs; a $7m approval milestone, 10% royalty and $23m in commercial milestones (with ludicrously high annual sales triggers)." Time will tell.
A potential $17m cash injection later this year would represent almost 50% of the current MCap and should have some positive impact on the sp.
Thanks Italian. Very interesting and potential significant development. Not sure why this is not highlighted up front?
WE ARE HIRING: TECHNICAL PROJECT MANAGER
Currently, we are looking for talented and motivated Technical project managers.
Responsibilities:
- Coordination of the SaaS development project team
- Adjusting development methodologies and workflow to improve speed and reliability
- Supporting tasks throughout whole lifecycle, from analysis to deployment
- Managing, adjusting and approving any changes in project scope, schedule, design and/or budget
- Identifying and mitigating potential risks
- Managing the relationship and communication with the client and stakeholders
- Defining metrics and criteria for performance, testing and product acceptance
- Writing specifications and technical documentation
Requirements
- Experience in program or project management
- Experience managing group goals, driving timelines, and organizing/presenting data
- Experience in the implementation of Agile development methodologies
- Communication skills in English
- Knowledge of cost dev / jobs-to-be-done methodologies, ability to form product hypotheses and understand how to test them and make decisions based on them;
- Ability to use analytics services (at least one): Google Analytics, Amplitude, Appsflyer. AppMetrica;
- Understanding of the main marketing metrics: CPI, CPA, Arpu;
- Experience in working and building end-to-end analytics
Tools we use to work efficiently:
- Jira, Slack, Confluence, Miro, Figma
What we offer:
- Work in innovative industry and emerging market
- Competitive compensation depending on experience and skills
- Friendly, creative and cohesive team
I have suffered severely with (PE), and it has been a complete ruin to my love life and relationships. I have been divorced 4 times as a result of my (PE) problems. I need help and I am willing to do whatever I can to possibly be treated for this issue.
https://www.morarimedical.com/
Thanks Bignose, indeed too many mechanical problems with the Td5 engine so I had to change it to a 4 cyl and since then no problems but do miss the sound of the old Td5 motor.
Dougie, we hit 79c in Dec 2016 just on the GB roll out news and we have come a long way since then with
OTC approval in EU, Israel and Balkan license agreements, roll out in Taiwan, HK and Macao, China clinical trials
to commence in China shortly, Phase II completed in USA, DVP sp surge etc.. so if we can manage to kick a few goals
and tap into a rebounding HK market with some positive announcements I think $1 is certainly achievable within the next
year or two. There will most likely be further developments in the growing longevity sector which could also assist in boosting the SP. Important to keep in mind that our current MCap is only 32m squid (ie under shell value) so the potential is there to go well above HK$1 if things fall into place. Management have significant skin in the game and I am sure they do their utmost to kick things along. I can smell the bacon
Bignose, I currently have a Defender 110 Td5 model, my 3rd Land Rover and 2nd Defender. Lots of mechanical problems over the years lol, but still in love with Defenders. If ERP goes to +$1 I will certainly consider upgrading to the new Defender model for more comfort. The standard model is not that flash but add a few extras and they look great. The INEOS Grenadier is also worth considering. Sounds good with the Defender in Norway. Bring on 2022!
Merry Christmas Bignose and all. Congratulations on the new Qashqai. Still happy with my Defender but it
would probably not qualify for the Singapore roads lol
JP Morgan predict a sharp c. 40% rebound in the HK market in 2022 and I am confident we will benefit from the positive sentiment. 2022 should be a rip roarer with steady positive news flow in a rising market.
Onwards and upwards!
Good post Bignose. First time I have invested in pharma, it is a risky sector but with potential massive rewards. Certainly a waiting game. Not always things pan out well just look at Oncopeptides and Mountain Valley MD (which was promoted again and again on this bb by Charlie). MV is currently trading at 11c after a high of $2.29 back in February. ONCO was trading at 215 kr in February and is now at 8.8 kr. I am sure Endurance will deliver in due course. When Fortacin is finally on the shelves around the world the MCap will be multiples of 33m squid.
It sounds like the board is simply investigating the potential of a shift in regulatory strategy in order to speed things up.
"The Company’s CRO has requested a RLD Type C meeting with the FDA for the purposes of obtaining feedback from the division on the RLD protocol before the EOP2 meeting." As such the FDA feedback will be critical wrt a potential new strategy.
I agree with The.Italian that we are inching slowly forward. Not as fast as we wish but still progress on all fronts. I am very pleased that we are joining forces with Tel Aviv based SK Pharma Group. I notice they have world wide offices including Russia and Belarus so maybe they can assist us in expanding into these countries in due course. We might get a separate update on DLI developments when there is some tangible progress to report. Funding for 2022 is not an issue as we can very easy offload our DVP holding (which is still undervalued).
November 29, 2013, Chalgrove, United Kingdom - Plethora Solutions Holdings, a speciality pharmaceutical company, announces that Ronald Openshaw will step down from the board and resign as chief executive officer, effective November 30, 2013.
Mr. Openshaw has a significant track record in life sciences and healthcare sectors both in executive management and in an advisory role. He is the founder of the M&A and strategic consulting firm Lucia Capital LLP and previously he spent many years as an investment banker at Panmure Gordon & Co. Limited (latterly WestLB Panmure Limited) and then most recently Jefferies International Limited.
Mr. Openshaw also served as CFO and acting CEO at Pharmagene plc until its merger with Asterand plc in 2006, where he remained as CFO to complete the integration in early 2007. He qualified as a Chartered Accountant with KPMG.
RO on LinkedIn with an outdated headline stating: 2020 a year for Vision - Strategy - Action...
Lucia Capital Consulting has been my consultancy vehicle since 2008. Over that period I have helped many companies achieve a number of goals in corporate strategy, mergers, acquisitions, and disposals. In 2013/14 I helped Simbec Research - recently acquired by the Wales Life Sciences Fund - to acquire Orion Clinical. This led to my appointments as CEO of Simbec-Orion. Following my departure from this role I am now taking on a number of interesting projects, until a new C-suite role takes up my working day. ... Not a word about Plethora Solutions, I wonder why? The departure as CEO for PS was very abrupt, announced one day and gone the next with no acknowledgement wrt his contribution in moving the coy forward...
Thanks Bignose. Let's see how it all pans out. I am hopeful our patience will be well rewarded $$$$$$$$$.
Bothwell, on AUG 28 you noted: "His (ie. Alquemie) comments seem like someone who knows the facts, from a good basic training but decides to twist them…….hallmarks of an employee “who has been let go” ? Could be licensor trying to knock the price down (joke)."
"Who is right or wrong will play out over the next 12-18 months. As I’m sure you appreciate as the information could be price sensitive I can only expand slightly beyond what is on the website. On that basis, until we are over the goal line I can’t answer and more bb questions……apologise to the guys please but at this stage lots of interested parties are trying to get information."
I guess these are e.mail extracts from Dr Mike Wyllie and I find solace from the last bit part about lots of interested parties in the USA are trying to get information.
It is also important to remember that Bignose is a major holder in direct contact with Dr Mike Wyllie and he did not run for the hills unlike Charlie. I hope Charlie is OK after investing in AMC and Mountain Valley MD.
Strong finish from DVP yesterday @ 84c (on the old scale) with our holding now valued at $HK$101,354,352 or 30.6% of the MCap. If DVP is awarded the Bellevue Gold mining contract this month we should see a major leg up as the market will most likely assume other contracts will follow. Next months we will get 75% of the results from the recently completed $10m drilling program with resource upgrade to follow etc which should maintain upward sp momentum.